AngioDynamics (ANGO) reported fiscal 2027 first-quarter net sales of $80.9 million, up 6.9% from the prior-year quarter. The company recorded a GAAP net loss of $7.1 million, or $0.17 per basic and diluted share, compared with a $10.9 million loss, or $0.26 per share, a year earlier.
Med Tech sales rose 13.2% to $39.9 million, while Med Device sales increased 1.4% to $41.0 million. AngioDynamics reiterated its fiscal 2027 net-sales guidance of $336 million to $341 million.
- GAAP gross margin was 59.4%, up 410 basis points year over year.
- Auryon sales increased 14.7% to $18.9 million; NanoKnife sales rose 29.0% to $8.3 million.
- Cash used in operations was $15.3 million; cash at Aug. 31 was $34.0 million.
- Eric Honroth will become president and CEO effective Nov. 2, 2026, succeeding Jim Clemmer.
- The company received FDA IDE approval for the RELIEF feasibility study of NanoKnife IRE in benign prostatic hyperplasia.
$ANGO Insider Trading Activity
$ANGO insiders have traded $ANGO stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ANGO stock by insiders over the last 6 months:
- WARREN JR NIGHAN (SVP Quality and Regulatory) sold 23,370 shares for an estimated $344,006
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ANGO Hedge Fund Activity
We have seen 81 institutional investors add shares of $ANGO stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 562,153 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,313,610
- ROYCE & ASSOCIATES LP added 440,884 shares (+28.8%) to their portfolio in Q2 2026, for an estimated $5,735,900
- BASTION ASSET MANAGEMENT INC. removed 389,732 shares (-29.7%) from their portfolio in Q2 2026, for an estimated $5,070,413
- WESTERN STANDARD LLC added 387,188 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,037,315
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 374,029 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,866,117
- AQR CAPITAL MANAGEMENT LLC added 337,643 shares (+134.2%) to their portfolio in Q2 2026, for an estimated $4,392,735
- ARMISTICE CAPITAL, LLC added 329,000 shares (+17.6%) to their portfolio in Q2 2026, for an estimated $4,280,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
